lifesciencelaw.ch
The regulation of the life science industry has become ever more complex in recent years due to remarkable scientific advances.
The regulation of the life science industry has become ever more complex in recent years due to remarkable scientific advances.
News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: Haemovigilance Annual Report 2025
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
Swissmedic: Changes to the Guidance document “Import of a human medicinal product according to art. 14 para. 2 and 3 TPA (parallel import)”
-
Swissmedic: Adaptations required for issuing establishment licences and GMP certificates for manufacturers of active substances
-
European Medicines Agency: Global regulators call for advancing alternatives to animal testing
Publications
-
Publications |The EU AI Act: A New Layer of Regulation for AI-enabled Medical Devices
by David Vasella, Celine Weber and Lucina Herzog
PDF: 178 KB -
Publications |The new EU Urban Wastewater Treatment Directive (EU) 2024/3019 and its Impact on the Pharmaceutical and Cosmetic Industry In- and Outside the EU
by Celine Weber and Isabell Schellhas
PDF: 245 KB -
